Archit Organosys Board to Consider Fund Raising Proposal

AHMEDABAD, August 27, 2026 — Chemical manufacturer Archit Organosys Limited announced today that its Board of Directors will meet on Thursday, September 3, 2026, to consider and evaluate a proposal for raising funds.

The decision marks a key corporate move for the company as it explores capital expansion to support ongoing operational and business requirements.

Archit Organosys Board to Consider Fund Raising Proposal

Archit Organosys Limited formally submitted a regulatory intimation to stock exchanges on Thursday under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing confirms that the upcoming board meeting will focus on evaluating various financial instruments for capital augmentation.

The Gujarat-headquartered organic chemicals producer indicated that the proposed fund-raising effort may involve issuing equity shares, share warrants, or other equity-based instruments. The capital deployment plan remains subject to necessary statutory and shareholder approvals as mandated by Indian corporate regulations.

Permissible Issuance Modes and Capital Structuring

The company plans to evaluate multiple permissible funding routes during the scheduled September 3 meeting. Potential mechanisms include issuing securities through a preferential issue on a private placement basis, or utilizing other approved modes or combinations thereof.

Key structural elements outlined in the regulatory submission include:

• Issuance Formats: Equity shares, convertible share warrants, or other equity-linked securities.

• Placement Routes: Preferential issue via private placement or alternative regulatory mechanisms.

• Governance Standard: Execution subject to approval from board members, equity shareholders, and regulatory authorities.

Insider Trading Window Restrictions Implemented

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, Archit Organosys confirmed the immediate closure of its trading window for key company insiders.

The trading restriction applies directly to designated individuals, including promoters, directors, senior managerial personnel, connected persons, and their immediate relatives. The trading window will remain closed and will reopen 48 hours after the board's final decision is formally disclosed to the stock exchange.

The regulatory communication was officially signed and authorized by Kandarp Amin, Chairman and Whole-time Director of Archit Organosys Limited, at 19:36 IST on August 27, 2026.

Official Sources Section

According to official regulatory disclosures filed by Archit Organosys Limited with market authorities, the board will convene on September 3, 2026, to review funding options. The compliance submission was formally executed by Chairman and Whole-time Director Kandarp Amin.

Quote Section

According to officials, "The meeting of the Board of Directors is scheduled to be held on Thursday, 3rd September, 2026, inter alia, to consider and evaluate a proposal for raising of funds by the Company through one or more permissible mechanisms, including preferential issue on a private placement basis."

Why It Matters

Securing fresh capital provides Archit Organosys with financial liquidity to fund corporate expansion, strengthen operational capital, or reduce balance sheet leverage. For equity investors and market participants, preferential private placements often lead to changes in shareholding structures while providing capital for long-term project execution.

The immediate closure of the trading window ensures market transparency and prevents insider transactions ahead of the official outcome of the board's decision.

Key Facts at a Glance

• Board Meeting Date: Thursday, September 3, 2026.

• Primary Agenda: Evaluation of capital raising via equity shares, share warrants, or equity-linked instruments.

• Proposed Mode: Preferential issue on a private placement basis or other permissible modes.

• Trading Window Status: Closed for promoters, directors, and senior management until 48 hours post-announcement.

• Regulatory Authority: Filed under SEBI LODR Regulation 29 and SEBI PIT Regulations.

Frequently Asked Questions (FAQ)

What did Archit Organosys announce?

Archit Organosys Limited announced that its Board of Directors will meet on September 3, 2026, to evaluate proposals for raising funds.

How does Archit Organosys plan to raise capital?

The company is considering issuing equity shares, share warrants, or equity-based securities through a preferential issue on a private placement basis or other permissible modes.

When will the trading window reopen for company insiders?

The trading window will reopen 48 hours after the outcome of the September 3 board meeting is publicly disclosed.

Source: Official regulatory filings submitted by Archit Organosys Limited to BSE Limited on August 27, 2026.